Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2006)
13 slides from Cogstate's shareholder meeting presentation, Oct 26, 2006
Slide 1: Annual General Meeting 26 October 2006
Annual General Meeting 26 October 2006
Slide 2: Martyn Myer, Chairman
— Gogstate Martyn Myer Chairman
Slide 3: A year of progress
A year of progress • Simplified business model • Revenue growth of 102% • Focus of development and commercialisation of computer based tests of cognition • Strategic decision to focus on sales into the clinical trials market • Divestment of therapeutic portfolio • Major reduction in cash burn • Chan
Slide 4: Achievements throughout the year
Achievements throughout the year • Secured $1.3m product development funding from Pfizer • Placement raised $300k in December • 1:7 Rights Issue raised $550k in February • Appointed former Pfizer scientist, Prof. Peter Snyder as a consultant in the USA • Approval of our USA patent application • Secu
Slide 5: Brad O'Connor, Chief Executive Officer
Brad O’Connor Chief Executive Officer 5
Slide 6: Financial Result: June 2006
Financial Result : 30 June 2006 • Sales revenue $2.08m (2005: $1.03m) representing growth of 102% • EBIT loss of $1.95m (2005: $2.85m) • H1 EBIT loss $1.60m : H2 EBIT loss $0.35m • Restructure reduced operating costs by more than $0.80m for H2 6
Slide 7: Revenue growth by quarter
Revenue growth by quarter CogState sales revenue, by quarter 800 700 600 500 $'000 400 300 200 100 - 20 20 20 20 20 20 20 20 20 20 20 04 04 04 05 05 05 06 06 04 05 06 Ja Ju O Ja Ju O Ja Ju A A A pr pr pr ct ct n- l-S n- l-S n- l-S -D -D -J -J -J M M M ep ep ep un un un ec ec ar ar ar Revenue growth,
Slide 8: Quarterly cash flows since July 2005
Quarterly cash flows since 1 July 2005 1,000 800 600 400 200 - Cash Receipts $'000 2005 Jul-Sep 2005 Oct-Dec 2006 Jan-Mar 2006 Apr-Jun 2006 Jul-Sep Staff Costs -200 Cash Flow -400 -600 -800 -1,000 -1,200 Cash flow for Q1 2007 consistent with Q4 2006 8
Slide 9: Key players in the CNS market
Key players in the CNS market Aim to build relationships with world-class partners Specifically target 4-5 big pharmaceutical companies with central nervous system technologies Targeting potential large customers 9
Slide 10: Strategy for revenue growth
Strategy for revenue growth • Continued use of technology by Pfizer • Agreements signed with GlaxoSmithKline, Merck & Lundbeck • Establishment of US office • Continue to focus on large pharmaceutical companies with pipeline of CNS drugs • Ensure we have the best product and the best people 10
Slide 11: Continued investment in R&D
Continued investment in R&D • Secured $1.3m of product development funding from Pfizer • Working in conjunction with Pfizer & Yale to develop pediatric tests • Development of dedicated batteries of tests for Schizophrenia, ADHD and MCI • Launch of DataPoint, the world’s first real- time cognitive da
Slide 12: Outlook
Outlook • Expansion of sales and marketing operations in the US, including new staff • Continue to foster close relationships with “big pharma” companies • Continue excellent revenue growth • Expanded product offering 12
Slide 13: Brad O'Connor, Chief Executive Officer, CogState
Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 [email protected] 13